Welcome to our dedicated page for Geron SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Geron Corporation (GERN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies, Geron uses its SEC reports to detail financial performance, material events, clinical progress and corporate actions related to its telomerase inhibitor RYTELO (imetelstat) and broader business.
Investors can review current reports on Form 8-K that Geron has filed in connection with key developments. Recent 8-K filings have addressed topics such as quarterly financial results and business highlights, 2026 financial guidance for RYTELO net product revenue and total operating expenses, a strategic restructuring plan including a reduction in workforce, executive leadership changes, and amendments to compensation and inducement award plans. These filings provide formal context for press releases and outline the board-approved actions and estimated financial impacts of restructuring and other initiatives.
In addition to 8-Ks, Geron’s periodic reports on Forms 10-K and 10-Q (accessible through EDGAR and summarized on this page when available) typically include detailed financial statements, discussion of revenue sources, risk factors, clinical program descriptions and capital structure information. For a company like Geron, these filings are central to understanding how RYTELO product revenue, license fees and royalties fit within its overall operating results and cash position.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, updates on the IMpactMF Phase 3 trial in myelofibrosis, or the scope and cost of restructuring plans. Users can quickly identify important disclosures without reading every line of the underlying documents. The platform also surfaces insider and equity-related information reported in connection with inducement grants and executive compensation arrangements, helping investors monitor how management and employees are incentivized.
Because Geron’s strategy depends on clinical and commercial execution in hematology-oncology, its SEC filings are a primary source for tracking progress, risks and governance decisions. This page brings together those documents and AI-driven insights so that investors can efficiently evaluate GERN’s regulatory history and ongoing obligations.
Event: Geron Corporation (GERN) filed an 8-K reporting the appointment of Harout Semerjian as President, Chief Executive Officer and director, effective August 7, 2025.
- CEO appointment: Mr. Semerjian replaces Dawn C. Bir and will fill a Class I board vacancy through the 2027 annual meeting.
- Compensation: Annual base salary $800,000; annual performance target bonus 70% of base salary (prorated for 2025).
- Equity inducement: Grant of stock options to purchase 11,000,000 shares under the 2018 Inducement Award Plan; exercise price = Nasdaq closing price on start/grant date.
- Vesting: 7,000,000 options: 12.5% at six months then monthly over 42 months; 4,000,000 options: 25% at one year then monthly over 36 months; full vest upon Change in Control.
- Severance: Covered Termination: prorated target bonus, lump-sum equal to 18 months base salary, COBRA for up to 18 months; vested options remain exercisable until earlier of two years post-termination or original expiration.
- Plan amendments: Amended and Restated Severance Plan effective August 1, 2025 adds a CEO payment equal to 150% of target bonus upon a qualifying Change of Control; 2018 Inducement Award Plan amended to add 11,000,000 shares for inducement grants.
- Exhibits: Employment Agreement (Exhibit 10.1), Amended Severance Plan (Exhibit 10.2), Amended 2018 Inducement Plan (Exhibit 10.3).